Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA) as a personalized biomarker

AACR 2025 abstract CT132 of NCT03575611: median PFS 18 months and median STFS 34 months in 121 patients; baseline ctDNA MRD+ in 56%, with shorter STFS (HR 2.9, 27 vs 54 months); 31% of baseline-MRD+ patients converted to MRD– at 3 months, and 3-month MRD+ was associated with shorter STFS (HR 4.3).

AACR Annual Meeting 2025, Abstract CT132 2025